Abstract：
OBJECTIVE: The current systematic review aimed to collect and analyze all available published and unpublished cases in which prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (177Lu-PSMA) was used to treat non-prostatic cancer.
METHODS: Literature search and evidence acquisition through contacts with organizations that use 177Lu-PSMA were employed. PubMed/Medline, SCOPUS, and ScienceDirect searches were performed following PRISMA recommendations. The search strategy was to screen all articles describing 177Lu-PSMA radioligand therapy published to date with the key word \"177Lu-PSMA\". These articles were collected and screened for non-prostatic cancer cases. Quality assessment was performed using the GRADE criteria.
RESULTS: A total of 713 articles were screened, and the search revealed 15 eligible records. Forty patients with a mean age of 51.2±18.5 years were treated with 177Lu-PSMA for non-prostatic cancer. Of them, 30 cases were published, and 10 were found in medical institution records. Cancers of the salivary glands were most often targeted (13/40), followed by various brain cancer types (8/40), and osteosarcoma (6/40). The authors used previously established protocols for castration-resistant prostate cancer with the dose per cycle as 6.0-7.4 GBq and the number of cycles between one and four. Toxicity was estimated as low, and 21 out of 28 patients with reported outcomes survived to the time of the publication.
CONCLUSIONS: PSMA-targeted radioligand therapy was infrequently used to treat different non-prostatic cancer types in various target organs. These pioneering efforts indicate that 177Lu-PSMA can be used to treat non-prostatic cancer with PSMA expression. The toxicity of such treatment was low, and the outcome was relatively good.
METHODS: Literature search and evidence acquisition through contacts with organizations that use 177Lu-PSMA were employed. PubMed/Medline, SCOPUS, and ScienceDirect searches were performed following PRISMA recommendations. The search strategy was to screen all articles describing 177Lu-PSMA radioligand therapy published to date with the key word \"177Lu-PSMA\". These articles were collected and screened for non-prostatic cancer cases. Quality assessment was performed using the GRADE criteria.
RESULTS: A total of 713 articles were screened, and the search revealed 15 eligible records. Forty patients with a mean age of 51.2±18.5 years were treated with 177Lu-PSMA for non-prostatic cancer. Of them, 30 cases were published, and 10 were found in medical institution records. Cancers of the salivary glands were most often targeted (13/40), followed by various brain cancer types (8/40), and osteosarcoma (6/40). The authors used previously established protocols for castration-resistant prostate cancer with the dose per cycle as 6.0-7.4 GBq and the number of cycles between one and four. Toxicity was estimated as low, and 21 out of 28 patients with reported outcomes survived to the time of the publication.
CONCLUSIONS: PSMA-targeted radioligand therapy was infrequently used to treat different non-prostatic cancer types in various target organs. These pioneering efforts indicate that 177Lu-PSMA can be used to treat non-prostatic cancer with PSMA expression. The toxicity of such treatment was low, and the outcome was relatively good.
摘要：
目的：本系统综述旨在收集和分析所有已发表和未发表的前列腺特异性膜抗原（PSMA）靶向放射性配体治疗（177Lu-PSMA）用于治疗非前列腺癌的病例。
方法：通过与使用177Lu-PSMA的组织接触进行文献检索和证据获取。PubMed/Medline,Scopus,和ScienceDirect搜索是根据PRISMA建议进行的。搜索策略是筛选所有描述177Lu-PSMA放射性配体疗法的文章，关键词为“177Lu-PSMA”。收集这些文章并筛选非前列腺癌病例。使用GRADE标准进行质量评估。
结果:共筛选713篇,搜索结果发现了15条合格记录.40例平均年龄为51.2±18.5岁的患者接受了177Lu-PSMA治疗非前列腺癌。其中,发表了30个案例，在医疗机构记录中发现了10个。唾液腺癌是最常见的目标（13/40），其次是各种脑癌类型（8/40），和骨肉瘤（6/40）。作者使用先前建立的方案治疗去势抵抗性前列腺癌，每个周期的剂量为6.0-7.4GBq，周期数在一到四个之间。毒性估计很低，28例报告结局的患者中有21例存活至发表时.
结论：PSMA靶向放射性配体疗法很少用于治疗不同靶器官的不同类型的非前列腺癌。这些开创性的努力表明177Lu-PSMA可用于治疗具有PSMA表达的非前列腺癌。这种治疗的毒性很低，结果相对较好。
方法：通过与使用177Lu-PSMA的组织接触进行文献检索和证据获取。PubMed/Medline,Scopus,和ScienceDirect搜索是根据PRISMA建议进行的。搜索策略是筛选所有描述177Lu-PSMA放射性配体疗法的文章，关键词为“177Lu-PSMA”。收集这些文章并筛选非前列腺癌病例。使用GRADE标准进行质量评估。
结果:共筛选713篇,搜索结果发现了15条合格记录.40例平均年龄为51.2±18.5岁的患者接受了177Lu-PSMA治疗非前列腺癌。其中,发表了30个案例，在医疗机构记录中发现了10个。唾液腺癌是最常见的目标（13/40），其次是各种脑癌类型（8/40），和骨肉瘤（6/40）。作者使用先前建立的方案治疗去势抵抗性前列腺癌，每个周期的剂量为6.0-7.4GBq，周期数在一到四个之间。毒性估计很低，28例报告结局的患者中有21例存活至发表时.
结论：PSMA靶向放射性配体疗法很少用于治疗不同靶器官的不同类型的非前列腺癌。这些开创性的努力表明177Lu-PSMA可用于治疗具有PSMA表达的非前列腺癌。这种治疗的毒性很低，结果相对较好。
